Medicines
Home / Our therapy areas / Medicines
We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations.
Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.
Reporting of side effects
The safety of our patients is very important to us. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.
By reporting any side effects that you may experience, you are helping to provide more information on the safety of our medicines. Report a possible side-effect to AstraZeneca by 'report side-effect' below. If you are based in the UK, you can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
Oncology
Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.
Calquence
acalabrutinib
Enhertu
trastuzumab deruxtecan
Faslodex
fulvestrant
Imfinzi
durvalumab
Iressa
gefitinib
Koselugo
selumetinib
Lumoxiti
moxetumomab pasudotox-tdfk
Lynparza
olaparib
Orpathys
savolitinib
Tagrisso
osimertinib
Zoladex
goserelin acetate implant
Cardiovascular, Renal & Metabolism
Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.
Andexxa/Ondexxya
Coagulation Factor Xa (Recombiant), Inactivated-zhzo
Atacand, Atacand HCT, Atacand Plus
candesartan cilexetil
Brilinta/Brilique
ticagrelor
Bydureon
exenatide
Byetta
exenatide injection
Crestor
rosuvastatin
Farxiga/Forxiga
dapagliflozin
Komboglyze
saxagliptin and metformin HCl
Kombiglyze XR
saxagliptin and metformin XR
Lokelma
Sodium zirconium cyclosilicate
Onglyza
saxagliptin
Plendil, Modip, Splendil, Munobal, Flodil
felodipine
Qtern
dapagliflozin and saxagliptin
Seloken ZOK, Toprol-XL, Betaloc ZOK
metoprolol succinate
Symlin
pramlintide acetate
Tenormin, Tenormine, Prenormine, Atenol
atenolol
XIGDUO
dapagliflozin and metformin HCI
XIGDUO XR
dapagliflozin and metformin HCI extended-release
Zestril
lisinopril dihydrate
Respiratory & Immunology
Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.
Accolate, Accoleit, Vanticon
zafirlukast
Bevespi Aerosphere
glycopyrronium/formoterol fumarate
Breztri Aerosphere
budesonide/glycopyrronium/formoterol fumarate
Bricanyl Respules
terbutaline
Bricanyl Turbuhaler
terbutaline in a dry powder inhaler
Daliresp/Daxas
roflumilast
Duaklir Genuair
aclidinium/formoterol
Eklira Genuair/Tudorza/Bretaris
aclidinium, a LAMA
Fasenra
benralizumab
Oxis Turbuhaler
Oxis Turbuhaler
Pulmicort Respules
budesonide inhalation suspension
Pulmicort Turbuhaler
budesonide
Rhinocort
budesonide
Saphnelo
anifrolumab
Symbicort pMDI
budesonide/formoterol
Symbicort Turbuhaler
budesonide/formoterol
Tezspire
tezepelumab
Vaccines and Immune Therapies
Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.
Evusheld
tixagevimab and cilgavimab
Fluenz Tetra/FluMist Quadrivalent
influenza vaccine live, intra-nasal
Synagis
palivizumab
Rare Disease
Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.
Kanuma
sebelipase alfa
Soliris
eculizumab
Strensiq
asfotase alfa
Ultomiris
ravulizumab
Early access to AstraZeneca investigational medicinal products
We recognise that there are circumstances where patients with serious or life-threatening diseases have exhausted all available therapeutic options and may not be eligible to enrol in one of our clinical trials. In such circumstances individual patients may be eligible for early access to an AstraZeneca investigational medicinal product.
Veeva ID: Z4-51513
Date of preparation: December 2022